title: [A Markov model to access long-term effects of rosiglitazone natrium on the treatment of type 2 diabetes].
abstract: OBJECTIVE
  The aim of this study was to estimate the long-term treatment effects of Rosiglitazone-natrium in type 2 diabetes.
  
  
  METHODS
  A Markov decision model was developed to predict, over 10 years, mortality with or without Rosiglitazone-natrium treatment.
  
  
  RESULTS
  During 10 years research, 14.2% patients developed to complications of type 2 diabetes mellitus, 3.8% patients should be dead in Rosiglitazone-natrium treatment group. 22.7% patients developed to complications of type 2 diabetes, 6.6% patients should be dead in non-Rosiglitazone-natrium treatment group.
  
  
  CONCLUSIONS
  Markov decision model should be useful in accessing the long-term effects of drug treatment. Evidence on long-term benefit of Rosiglitazone-natrium could be of importance for future decision making.
authors.affiliation: West China School of Public Health, Sichuan University, Chengdu 610044, China.
authors.forename: Cai-Rong
authors.initials: CR
authors.lastname: Zhu
authors.forename: Zong-Zan
authors.initials: ZZ
authors.lastname: Ni
authors.forename: Ke-Hong
authors.initials: KH
authors.lastname: Sun
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008390:Markov Chains; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D013995:Time
chemical_list: D045162:Thiazolidinediones; D000077154:Rosiglitazone